ClinicaliQ Trial Snapshot
- Mechanisms of Atrial Pathoelectrophysiology in HCM — Recruiting • Cardiology / Cardiovascular • NCT07454135.
- What is being tested: This research investigates the underlying electrophysiological mechanisms responsible for the increased incidence and treatment resistance of atrial fibrillation in patients with hypertrophic cardiomyopathy, an inherited condition characterised by abnormal cardiac muscle thickening.
- Patient eligibility overview: The study focuses on individuals with diagnosed hypertrophic cardiomyopathy, with particular emphasis on those experiencing atrial fibrillation or at risk of developing this arrhythmia, enabling direct comparison of atrial electrical properties between affected and unaffected patients.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual. Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them. The information from this study may help improve future treatments for people…
Eligibility Snapshot
- : * Paroxysmal or persistent atrial fibrillation * Diagnosis of hypertrophic cardiomyopathy * Patient planning to proceed to atrial fibrillation ablation following clinical consultation * Age 18-80 years * Able and willing to provide written informed consent * Able and willing to comply with study follow up requirements
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.